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Here we revisit how dietary factors could affect the treatment of patients with complications of chronic kidney
disease (CKD), bringing to the attention of the reader the most recent developments in the field. We will briefly
discuss five CKD-induced complications that are substantially improved by dietary manipulation: 1) metabolic
acidosis and the progression of CKD; 2) improving the diet to take advantage of the benefits of angiotensin
converting enzyme inhibitors (ACEi) on slowing the progression of CKD; 3) the diet and mineral bone disorders in
CKD; 4) the safety of nutritional methods utilizing dietary protein restriction; and 5) evidence that new strategies
can treat the loss of lean body mass that is commonly present in patients with CKD.Background
When we published a Commentary on how dietary fac-
tors could affect the treatment of patients with compli-
cations of chronic kidney disease (CKD) in 2004, we
relied heavily on results from older publications [1].
There were two reasons for this decision: firstly, clini-
cians and investigators working on this topic were still
reeling from the negative conclusion of the Modification
of Diet in Renal Disease trial (MDRD), namely that diet-
ary modification exerted only a minor impact on the
progression of CKD [2]. Secondly, there were too few
hypotheses addressing how dietary manipulation could
affect the development of CKD and its complications
[1]. We now revisit this topic because new insights have
identified how dietary factors can overcome the develop-
ment of CKD and its complications, including the pro-
gression of CKD. Notably, these insights can be largely
traced to results obtained during rigorous studies of pa-
tients with CKD rather than intensive investigations of
animal models, indicating there is clinical relevance to
the reports. To illustrate why we are keen to bring these
developments to the reader’s attention, we will briefly
discuss in this article five CKD-induced complications
that are substantially improved by dietary manipulation.* Correspondence: mitch@bcm.edu
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can suppress complications of CKD
The genesis and treatment of metabolic acidosis has long
been a favorite teaching exercise for nephrologists [3].
This interest arises in large part because this complication
of CKD causes substantial loss of muscle mass [4–7]. The
scope of topics regarding the treatment of metabolic acid-
osis has grown substantially because it has been reported
that correction of metabolic acidosis by dietary manipula-
tion can effectively suppress the accelerated loss of kidney
function in patients with progressive CKD. This insight
was first detected when it was found that the serum levels
of bicarbonate were inversely associated with increases in
serum creatinine in the calculation of estimated GFR
(eGFR). For example, Shah et al., examined clinical chem-
istry results obtained from adults attending a University
Medical Clinic over a 2 year time period [8]. In their study
of 5422 patients with various kidney diseases, including
diabetic nephropathy, 337 patients were found to have evi-
dence of CKD progression as assessed by declining eGFR.
In patients with serum bicarbonate concentrations ≤ 22
mEq/L, the hazard ratio for the progression of kidney dis-
ease was 1.54 (95 % confidence interval; [C.I.] 1.13 to
2.09) after adjustment for potential confounders compared
to the reference group (serum bicarbonate levels, 25 to
26 mEq/L). Similar results were obtained using differ-
ent definitions of the renal outcome (i.e., 30 % decline
in eGFR or doubling of serum creatinine levels) [8].
In another analysis, values of dietary acid generation
were obtained from the 24-h dietary recall questionnairele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Diet enriched in fruits and vegetables
(calculated to reduce dietary acids by 50%)
CKD stage 2
(urine albumin-to-creatinine ratio > 200 mg/g creatinine,
eGFR 60-89 mL/min) 
Potential renal acid load
8-hr urine net acid excretion
Urine albumin-to-creatinine ratio
Urine TGF-
P < 0.001 
P < 0.001 
P < 0.05 
P < 0.05 
Fig. 1 Diet enriched in fruits and vegetables in amounts was
administered in order to reduce dietary acid load by 50 %. Patients
with stage 2 CKD who received this dietary intervention for 30 days
experienced significant improvements in the potential renal acid load,
8-h urine net acid excretion, urine albumin-to-creatinine ratio and urine
TGF-β. Abbreviations: CKD, chronic kidney disease; eGFR, estimated
glomerular filtration rate; TGF-β, transforming growth factor β. Results
from Goraya et al. [16]
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Trial [9]. In the 1468 adults with CKD participating in this
evaluation during 14.2 years, 311 participants developed
ESRD. The risk of ESRD was increased in patients ex-
pressing higher levels of dietary acid generation yielding a
relative hazard ratio of 3.04 (C.I.; 1.58 to 5.86) for patients
with the greatest degree of acid production.
Identification of the associations between metabolic
acidosis and the progression of CKD has understandably
stimulated investigators to examine if progression of CKD
could be suppressed by simply supplying alkali supple-
ments. De Brito-Ashurst and colleagues evaluated this pos-
sibility in a controlled trial of 134 adult patients with
metabolic acidosis (serum bicarbonate, 16–20 mM) and
CKD (basal creatinine clearances (Ccr), 15 to 30 ml/min/
1.73 m2) [6]. In that study, patients were randomly assigned
to standard care or to administration of bicarbonate supple-
ments; their Ccr levels were examined repeatedly over 2
years. The patients assigned to bicarbonate supplements ex-
perienced a slower decline in Ccr (−1.88 vs −5.93 ml/min/
1.73 m2; P < 0.0001) and fewer of the patients treated with
sodium bicarbonate developed ESRD (P < 0.001). The in-
vestigators also uncovered nutritional benefits of correcting
acidosis in patients with CKD, including evidence for in-
creasing protein stores. Other investigators have examined
patients with hypertension, CKD and relatively preserved
levels of eGFR (mean, 75 ml/min/1.73 m2) during a 5 year
period [10]. Enrolled patients were treated with ACEi and
then randomly assigned to receive sodium bicarbonate, an
equimolar amount of sodium chloride or a placebo. The
authors found that the rate of decline of eGFR (estimated
from plasma cystatin C levels) was slower while eGFR
values remained higher in the group of patients treated with
oral supplements of sodium bicarbonate compared to re-
sults from patients treated with sodium chloride or placebo.
These and other reports demonstrate that the correction of
metabolic acidosis not only slows the rate of loss of kidney
function but also can improve hormonal metabolism as
well as values of protein turnover [11]. Although it is
possible that measurements obtained in a larger clinical
trial might uncover different results, these clinical mea-
surements were collected in randomized, controlled trials
and hence, they offer overwhelmingly relevant reasons for
correcting metabolic acidosis in patients with CKD.
Do publications also document that dietary factors
influence the relationship between metabolic acidosis
and progression of CKD? The answer is yes because it is
known that the catabolism of dietary proteins, especially if
the diet supplied proteins of animal origin, is the principal
source of acid generation [3]. When the kidney is chal-
lenged with acid, such as by eating an animal-source pro-
tein diet, it increases levels of hormones (i.e., angiotensin
II, aldosterone, endothelin) that help it excrete the acid
over short-term observations [12, 13]. However, in thelong-term, high levels of these hormones worsen kidney
function [14, 15]. Consequently, limiting proteins in the
diet will reduce the generation of acid and should aid in
the correction of metabolic acidosis. Indeed, there is evi-
dence that protein restricted diets can also suppress the
progression of CKD. For example, in 2012, these relation-
ships were tested by Goraya and colleagues [16]. They re-
duced the daily amount of acid generated by simply
increasing fruits and vegetables in the diet. This recom-
mendation achieved the goal of reducing acid generation
by 50 % [16]. The strategy used by the investigators simply
amounted to increasing fruits and vegetables in the diet.
The amount of added fruit and vegetables was based on
adding what would be required for a 50 % reduction in
daily acid generation. For most of the patients, this
amounted to adding two to four cups of fruits and veg-
etables to their daily diets. In the clinical trial of the in-
fluence of adding these foods, hypertensive patients
with stages 1 or 2 CKD (presumably due to hypertensive
nephropathy) were treated with ACEi and outcome
measures were documented [16]. The measures studied
included a decrease in urinary markers of kidney damage,
namely N-acetyl beta-D-glucosaminidase and TGF-β1.
After 30 days, stage 2 CKD patients who were treated with
either sodium bicarbonate supplements or changes in the
diet designed to increase the content of fruit and vegetables
had comparably positive responses estimated from de-
creased appearance of markers of kidney damage (Fig. 1).
These positive results were obtained during studies of a
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were sufficiently intriguing that the investigators were
stimulated to undertake a larger trial [17]. In this second
clinical trial, hypertensive patients with stage 4 CKD (eGFR
of 15–29 ml/min/1.73 m2) and metabolic acidosis (i.e., total
CO2 < 22 mM) were randomly assigned to either daily
sodium bicarbonate supplements (1 mEq/kg/day) or to
an increase in dietary fruits and vegetables that was suf-
ficient to reduce dietary acid by 50 %. After 1 year of
treatment, the total CO2 had increased to a similar ex-
tent (compared to baseline values) in both the sodium
bicarbonate and fruits plus vegetables groups. Regard-
ing kidney functional outcomes, the eGFR calculated
from plasma cystatin C levels did not differ between
the groups but indices of kidney injury were lower in
patients treated with diets enriched in fruits and
vegetables.
These reports are encouraging for several reasons.
Firstly, there is evidence that simply supplying alkali to
patients with CKD and metabolic acidosis will result in
important clinical benefits that include slowing of pro-
gressive renal insufficiency and reversing the loss of
protein stores. Secondly, the dose of sodium bicarbonate
supplements or the amounts of dietary fruits and vegeta-
bles needed to block the development of metabolic acidosis
can be simply assessed by measuring the serum bicarbon-
ate (or total CO2). Thirdly, these outcomes should stimu-
late new hypotheses to design methods of correcting
metabolic acidosis or creating other dietary strategies.
Inadequate attention to the diet interferes with
methods of slowing progression of CKD
Designing the optimal diet for patients with CKD is dif-
ficult because of interrelationships among different nu-
trients. For example, when the diet plan includes a
reduction in dietary protein there must be a concomitant
increase in the intake of other nutrients to maintain the
requirements for calories. This is not the only problem
since the requirement for calories is also influenced by
CKD, because CKD results in the development of insulin
resistance and eventual impairment of carbohydrates and
lipids utilization [18, 19]. Moreover, designing meals must
also include recommendations about the intake of ions
and minerals. This is relevant because a high intake of
protein is generally accompanied by an increase in dietary
phosphates, salt, etc. This problem was highlighted when
it was reported that unregulated amounts of dietary phos-
phates or sodium chloride will interfere with the ability of
ACEi to suppress the progression of CKD. In one report,
Zoccali and colleagues pointed out that changes in the
levels of serum phosphate were positively correlated with
values of serum creatinine in 331 patients with proteinuric
nephropathies who were participating in the prospectively
designed Ramipril Efficacy in Nephropathy (REIN) trial[20]. The investigators found that independently of treat-
ment, patients with serum phosphate levels in the highest
two quartiles (3.45–4.00 mg/dL and > 4.00 mg/dL) pro-
gressed significantly faster, reaching ESRD or a com-
posite end-point of doubling of serum creatinine or
ESRD when compared to results from patients with
phosphate levels below the median (<3.45 mg/dL). Of
note, the renoprotective effect of the ACEi, Ramipril,
decreased as serum phosphate levels increased (P ≤ 0.008).
This association persisted even after the results were ad-
justed for confounders such as measured GFR and urinary
protein. The authors concluded that monitoring and redu-
cing serum phosphate by changing the diet should be a
principal goal in planning the diets of patients with CKD.
We recognize that the admonition to control serum
phosphorus by manipulating the diet can be very diffi-
cult because phosphates present in processed grocery
products are only infrequently posted on the food labels
[21]. For example, one test of the accuracy of food
levels concluded that 44 % of the best-selling items in a
grocery were found to contain phosphate additives, es-
pecially in prepared, frozen foods, package meat, bread,
soup, etc. Not only is the phosphate content of many
foods missing from the food content labels but there is
evidence that this source of additional phosphates is
clinically relevant: the analysis indicated that sample
meals comprised mostly of foods that frequently con-
tain phosphates amounted to 736 mg more phosphorus
per day when compared to meals prepared with additive-
free foods [21]. Notably, diets that are rich in animal-
source protein are rich in phosphates [22]. Sherman and
Mehta investigated the ratio of the phosphorus in meat,
fish, and poultry meats and uncovered that the phos-
phorus content of 1 g of protein varied from 6.1 to 21.5
mg. Based on this information, it is not difficult to under-
stand how restricting dietary protein can reduce the risk
of adverse outcomes from high phosphate diets, including
renal osteodystrophy, left ventricular hypertrophy and
progression of CKD. In short, without careful dietary plan-
ning which includes the phosphate content of different
foods, the benefits of ACEi therapy on progression of
CKD and the prevention of renal bone disease will be
eliminated.
Phosphates are not the only potentially harmful nutrients
associated with protein rich foods. For example, sodium
chloride is often added to processed foods to improve their
“shelf life” plus the taste of the food product, specifically
foods that are pre-prepared or are in the category of “fast
foods”. As occurs with the high phosphate content of
protein-rich foods, responses to a high salt diet can inter-
fere with the ability of ACEi to suppress progression of
CKD. A post-hoc analysis of the REIN trial showed that
among 500 patients with proteinuric CKD receiving ACEi
therapy, those with a high dietary sodium intake (i.e., >14 g
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ESRD compared to those assuming less than 7 g of salt
daily [23]. Moreover, urinary proteins decreased more in
patients with low-or-medium sodium diet than in those in
high-sodium intake group. The excess risk of ESRD was in-
dependent of blood pressure control and was largely ex-
plained by the blunted antiproteinuric effect of ACEi
therapy in the setting of sodium overload [23]. Conse-
quently, a diet containing an excess of sodium chloride,
like that of diets with unregulated phosphate intake, can
blunt the antiproteinuric effect of ACEi while increasing
the risk for developing ESRD.
Dietary changes ameliorate mineral bone
disorders of CKD
Chronic kidney disease-mineral and bone disorder
(CKD-MBD) is a systemic dysfunction of mineral and
bone metabolism in patients with CKD. It results from
abnormalities in calcium, phosphorous, parathyroid hor-
mone and/or vitamin D metabolism as well as abnor-
malities in bone turnover, mineralization, volume, linear
growth or strength, in addition to vascular or other soft
tissue calcification [24]. Phosphate retention plays a cru-
cial role in the development of CKD-MBD and it also in-
creases the risk of cardiovascular events and mortality in
patients with CKD [25, 26]. In the early stages of CKD
serum phosphate levels are maintained in the normal
range through phosphaturia induced by increase in para-
thyroid hormone actions and fibroblast growth factor-23
(FGF-23) production. However, as kidney disease pro-
gresses the compensatory rise in FGF-23 levels fails to
sustain phosphate clearance sufficiently and hyperpho-
sphatemia ensues. Notably, increased FGF-23 levels by
itself has been associated with increases in both cardio-
vascular events and mortality [27, 28], suggesting that
control of phosphate homeostasis early in CKD may
help reducing the clinical consequences of mineral and
bone disorders. Strategies to manage elevated serum
phosphorus levels include reduction of dietary phosphate
intake, as well as the use of phosphate binding agents.
Clinical studies have assessed the effects of dietary phos-
phate and protein restriction in CKD patients. For ex-
ample, patients with advanced CKD (stages 4 and 5) who
had a reduction in dietary phosphates and protein intake
also had improved short-term control of secondary hyper-
parathyroidism [29–32]. In the long term, altering the diet
allowed some patients to achieve a normal rate of bone
formation [33]. Recent evidence suggests that in addition
to the absolute amount of phosphate in the diet, its source
(i.e., plant versus animal food) should be considered [34].
Indeed, dietary phosphates from plant-derived proteins
are mostly in the form of phytates, which are less digest-
ible in humans. Consequently, phosphates are ultim-
ately less bioavailable compared to phosphates derivedfrom animal sources [34]. Moe et al. addressed this
issue in nine patients who had established CKD (mean
eGFR 32 mL/min/1.73 m2) by comparing their re-
sponses to vegetarian- or meat-based diets with
equivalent contents of protein and phosphates. After
one week of the dietary intervention in their crossover
study, the vegetarian diet led to lower serum levels of
phosphorus and FGF-23 than the meat-based diet [35].
Moreover, 13 patients with stages 3–5 CKD converted
their food choices from an animal protein-based diet
to a 70 % plant-protein diet for four weeks. The result
was a significant reduction of urinary phosphorous ex-
cretion [36] even though there were no significant
changes in serum phosphorous or FGF-23 levels. The
urinary sodium and titratable acid contents significantly
decreased with the change to plant-based foods [36].
Overall, the combination of phosphate-restricted diets
plus oral phosphate binders has become a well established
approach to controlling serum phosphorus levels in pa-
tients with CKD stages 3–5 (including CKD stage 5D)
[24]. For example, a randomized controlled trial showed
that dual intervention with a low-phosphorous diet and
the addition of phosphate binders was more effective
than either approach alone in reducing serum FGF-23
concentrations in 39 patients with CKD stages 3–4 and
normal serum phosphate levels [37]. Taken together,
the results we have discussed suggest that restriction
of dietary phosphate intake may improve the control
of mineral and bone metabolism in CKD patients.
Nevertheless, the prescription of low phosphate diets
can be challenging in that the bioavailability of phos-
phates in foods (see above) needs to be considered.
Is the low protein diet-ketoacid regimen
nutritionally adequate?
The MDRD Study of nondiabetic patients with stage 4
CKD, was designed to examine the effects of restricted
dietary protein and blood pressure control on the rate of
decline in measured GFR in 255 patients [2]. During ap-
proximately 2 years of study, patients were treated with
either a low-protein (0.58 g/kg/day) diet or a very low-
protein diet (0.28 g/kg/day) that was supplemented with
a special mixture of essential keto acids and amino acids
(KA regimen). Adverse outcomes associated with the di-
ets included the development of kidney failure (initiation
of dialysis therapy or transplantation), death or a compos-
ite outcome of kidney failure or death. It was concluded
that the frequencies of these outcomes between the two
dietary regimens were scarcely different; there was only a
slightly slower decline in GFR associated with the very
low protein-KA regimen. Following the announcement
of this conclusion, the manufacturers of the essential
ketoacid-amino acid mixture stopped their production
of ketoacids and amino acids; the availability of
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aged to design their own diets. Over the ensuing 10
years after the MDRD Study ended, data regarding dietary
changes, nutritional measurements and the development
of other diseases were not evaluated systematically. Con-
sequently, it is difficult to evaluate the report that during
the 10 years following the end of the MDRD Study, the
frequency of death in patients treated with the ketoacid
regimen was higher than the rate occurring in patients
assigned to the low protein, non-supplemented diet
[38]. Specifically, insights or conclusions about death
rates that occurred following participation in the MDRD
trial are not possible because there were no records of dif-
ferences in compliance with the dietary regimens during
the MDRD trial or types of diets after cessation of the
MDRD trial, types of renal replacement therapy, variability
in health status, drug treatment regimens, etc. during the
years following the end of the MDRD Study. Still, the re-
port did stimulate other investigators to examine the ef-
ficacy and toxicity of the very low protein, KA regimen.
Chauveau and colleagues examined the long-term out-
comes of patients with CKD stage 4–5 who were treated
with a ketoacid-supplemented very low protein diet [39].
Among the 251 patients they enrolled, approximately 8.4
% discontinued the diet regimen within less than 3
months. The final analysis focused on 203 patients who
were given the dietary treatment for more than 3 months
(mean duration 3 years) before starting renal replacement
therapy. The investigators reported that the survival rates
in the study population receiving renal replacement ther-
apy after stopping treatment with KA-supplemented very
low protein diet were 79 % and 63 % at 5 and 10 years, re-
spectively [39]. There was no evidence that the KA regi-
men jeopardized the survival of 102 patients who were
subsequently treated by chronic dialysis nor was there re-
duced survival of 101 patients who received a kidney
transplant. In fact, they reported there was no correlation
between death rates in patients treated by the KA regimen
and the duration of treatment with the KA regimen. Why
the outcomes between investigators in France [39] and the
Menon [38] report are so different is not known but the
paucity of information about events, illnesses, etc. of
MDRD patients treated with the KA regimen indicates we
are unlikely to obtain the information needed to identify
explanation(s) for the differences. Nevertheless, the report
by Chauveau and colleagues provides evidence that long
term ketoacid-based dietary regimens are nutritionally
sound, at least in those who were compliant to the therapy
[39, 40]. Moreover, there is reassuring, albeit limited, in-
formation about the utility of dietary treatment in patients
who are at increased risk of adverse outcomes, namely,
elderly individuals with advanced renal insufficiency.
Brunori and colleagues examined the outcomes of
different treatment regimens for elderly (≥70 years)patients without diabetes but with advanced renal in-
sufficiency (i.e., eGFRs of 5 to 7 mL/min.) [41]. In their
report, patients were randomly assigned to either a very
low protein, vegan diet that was supplemented with
ketoacids (56 patients) or to dialysis without dietary
intervention (56 patients). Over the median treatment
period of 26.5 months, the death rates of the two
groups of elderly patients were not statistically different
nor were the survival rates obtained following one year
of the therapies when the outcomes were subjected to
an intention-to-treat analysis. The authors concluded that
the very low protein diet supplemented with ketoacids
was a safe method for postponing dialysis treatment for
non-diabetic, elderly patients. Notably, these outcomes
were examined by a cost-benefit analysis [42]. It was es-
timated that each patient treated with the low dietary
protein, KA regimen diet saved the National Health
Service 21,180 euros per patient when dialysis was
postponed for 1 year.
The most recent analysis of responses to dietary modi-
fication and the efficacy of the very low protein diet sup-
plemented by the ketoacids was reported by Garneata
et al. [43]. These investigators conducted a prospective,
randomized controlled trial to assess the safety and effi-
cacy of a ketoacid-supplemented very low protein regimen
(0.3 g dietary protein/kg/day) compared to a conventional
low protein diet (0.6 g dietary protein/kg/day) in non-
diabetic patients with <30 ml/min/1.73 m2 GFR and < 1 g
urinary protein/g creatinine. The trial was designed to test
responses to the very low protein diet-KA regimen rigor-
ously because the investigators tested patients for dietary
compliance and only enrolled patients who demonstrated
compliance. As expected, achieving the desired character-
istics for enrolling patients required screening of a very
large number of individuals (more than 1400) between
March, 2006 and April, 2009. Thus, the trial encompassed
104 patients treated with the KA regimen and 103 patients
treated with the conventional low protein diet. Both types
of nutritional interventions were safe, as reflected by
stable anthropometric and biochemical parameters (e.g.,
body mass index, serum albumin, or estimates of muscle
mass). Regarding efficacy in avoiding end-stage renal dis-
ease, evidence from the intention-to-treat analysis led the
authors to conclude that 55 patients reached the primary
composited efficacy end point (i.e., initiation of dialysis or
a >50 % reduction in eGFR). Importantly, only 13 % of pa-
tients in the KA regimen group reached the pre-specified
end points while 42 % in the conventional low protein diet
group reached the end points (P < 0.001). These outcomes
were also used to calculate the adjusted number of pa-
tients needed to treat with the very low protein diet KA
regimen for 1 year to avoid reaching the composite
endpoint, that was only 4.4 CKD patients. Notably, it
was determined that the serum bicarbonate levels for
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compared to only 16 mM for patients treated with the
conventional low protein diet. The authors concluded
that the very low protein diet KA regimen is nutrition-
ally safe and could defer for almost 1 year the need for
dialysis in patients with eGFR <30 ml/min/1.73 m2
[43]. Although the clinical outcome achieved with the
very low protein diet KA regimen was significant, the
participants were relatively well-selected and motivated
underscoring the challenge for investigators to uncover
methods of improving compliance and efficacy of diets
for patients with CKD. The low enrollment rate of the
Garneata trial [43] may also suggest that for CKD pa-
tients the choice of low-protein diet regimen or dialysis
are not equivalent. This possibility could be tested in
observational studies where patients will be assigned to
low-protein or conventional diet according to their will.
Why is dietary counseling used so infrequently? We
believe there are four major reasons: 1) designing the di-
ets is complex and requires a skilled dietician which
can be costly (in the U.S., this cost is paid for Medicare
recipients). 2) Changing the diet can be complicated
when there are other illnesses. 3) There is concern that
low-protein diet could cause loss of protein stores or
other complications. 4) The outcomes from the MDRD
trial led to the conclusion that low-protein diets did
not significantly slow progression in non-diabetic,
CKD patients.
New strategies to improve lean body mass, a
complication of CKD
In patients with CKD, muscle wasting and limited phys-
ical performance can substantially contribute to reduced
confidence and the risk of injuries. This is especially true
for patients who are bedridden or immobile [44]. For ex-
ample, measurements of the physical status of 385 pa-
tients with stages 2–4 CKD, uncovered a reduction in
muscle mass plus variabilities in the functional abilities
of different muscles [45]. The authors concluded that
patients with CKD were characterized by leg perfor-
mances that were at least 30 % lower than predicted
while handgrip strength was relatively preserved. The
major abnormality in muscle functioning was a reduc-
tion in measurements of walking speed and the “timed
and up and go” testing. The presence of these abnormal-
ities predicted a 3-year risk of death, was more reliably
than variations in the degree of CKD or the presence of
other biomarkers, and when eGFR levels were combined
with measurements of walking, the mortality predictions
were more accurate. In summary, impaired physical per-
formance of the lower extremities is common in CKD
and strongly associates with all-cause mortality.
The results we have highlighted raise the questions
whether it is possible to prevent loss of muscle mass andwould success in this goal improve the physical perform-
ance of patients with CKD to ultimately reduce their
risks of mortality? Devising methods that prevent muscle
loss has long been a goal of the treatment of patients
with CKD. As noted earlier, correction of metabolic
acidosis not only prevents muscle wasting in animal-
based models of CKD but also improves nutritional indi-
ces of patients with CKD and metabolic acidosis [4, 6].
The mechanisms underlying the loss of muscle mass in
rodent models of CKD (and other catabolic conditions)
have been closely linked to the development of insulin
resistance, the generation of inflammation and the activa-
tion of proteolysis in the ubiquitin-proteasome [19, 46–49].
Recently, methods have been designed that can suppress
the protein wasting stimulated by insulin resistance and/or
inflammation. For example, it is possible to block inflam-
mation and muscle wasting that develops in mice with
CKD by inhibiting myostatin [47]. Similarly, blockade of
Stat3 has been found to suppress both muscle wasting and
the generation of inflammatory cytokines, suggesting that
these inhibitors may have transitional relevance [48]. We
recognize that these are only the first steps in the goal of
devising a method that safely improves muscle mass and
obviously, this will require intensive testing in patients with
catabolic conditions, including CKD.
Conclusions
We conclude that integrating dietary manipulations into
a comprehensive strategy will help prevent or ameliorate
complications of CKD including acidosis, hyperkalemia,
hyperphosphatemia and uremic symptoms and possibly
influence CKD progression. We believe particular atten-
tion should be paid: 1) to correcting metabolic acidosis
with either sodium bicarbonate supplements or more
simply with diet instructions how to include supple-
ments of fruits and vegetables; and 2) to lower the intake
of sodium chloride as well as phosphates by choosing
foods that provide low contents of these ions. Changing
the diet by concentrating on these dietary constituents will
allow us to maximize the renoprotective anti-proteinuric
effect of renin angiotensin system blockers. These consid-
erations on dietary approaches for CKD prevention and
management are particularly valuable for low-resource
setting worldwide where patients with CKD are beset with
numerous challenges often traceable to poverty and a lack
of access to life-saving dialysis and transplantation [50].
The feasibility of these management approaches for CKD
and its risk factors even in low-income countries is exem-
plified by the program set up in the communities of East-
ern Nepal in collaboration with the International Society
of Nephrology (ISN) [51]. Dietary recommendation of
low-sodium intake and increase of fruits and vegetable
together with low-cost anti-hypertensive, anti-diabetic
or renoprotective drugs as deemed appropriate, have
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tion decline in more than a third of 3,400 individuals
on active monitoring.
Regarding the very low protein diet with essential keto
acids and amino acids regimen, there is recent and re-
assuring evidence for its efficacy and nutritionally safety
but efforts are needed to improve compliance with dietary
regimens. Nutritional educational programs and dieticians
could help to increase patient adherence to dietary recom-
mendations. We also recommend that components of the
diet and regular monitoring of nutritional status should be
jointly assessed by physicians and dieticians, just as rec-
ommended for patients with inherited metabolic defects,
cirrhosis and diabetes.
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